Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P21918

UPID:
DRD5_HUMAN

ALTERNATIVE NAMES:
D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor

ALTERNATIVE UPACC:
P21918; B2R9S3; Q8NEQ8

BACKGROUND:
The D(1B) dopamine receptor, identified by the UPACC code P21918, is integral to dopamine-mediated neurotransmission. This receptor's activation by G proteins, leading to adenylyl cyclase activation, underscores its importance in modulating neuronal activity and behavior. Known alternatively as the Dopamine D5 receptor, its involvement in dopamine signaling pathways is critical for various cognitive and motor functions.

THERAPEUTIC SIGNIFICANCE:
The association of the D(1B) dopamine receptor with benign essential blepharospasm, a disorder characterized by involuntary eyelid spasms, underscores its therapeutic significance. Exploring the receptor's role in this condition offers a promising avenue for developing targeted treatments that could alleviate the visual disturbances and improve quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.